Speakers

Expand/Collapse

Adam Wilkinson
Pre-Clinical Development
Microbiotica

Track B - Evening - Day One

4:45 pm | A Clinically-Defined Multifunctional Bacterial Consortium for the Treatment of Ulcerative Colitis

Alex Stevenson
CSO
4D Pharma PLC

Day Two

Thursday, 27th January 2022

9:55 am | Taking the Microbiome Beyond the gut – Realizing the Full Potential of Microbiome Therapies Through Targeted Systemic Effects

Alice Eggleston
Physician Assistant
Atlantia Food Clinical Trials

Track B - Afternoon - Day One

2:15 pm | 5 Tips for Successful Clinical Trials Implementation

Anders Damholt
Head of Clinical Development
Chr. Hansen

Day Two

Thursday, 27th January 2022

10:45 am | Discover how Biomarkers are Developing & Validating Therapeutic Targets

Barbara McGovern, M. D.
VP Medical Affairs
Seres Therapeutics

Day 2 - Track B Afternoon

2:15 pm | ECOSPOR III data

Benjamin Hadida
CEO and Co-Founder
Exeliom Bio

Day 2 - Track B Afternoon

2:45 pm | A Case Study Story Exploring the Pathway to Drug Development Surrounding IBD

Bernard Walther
Director, Drug Safety and Pharmacokinetics
Servier

Day 2 - Track A Evening

5:15 pm | Medicen Initiative

Celine Druart
Pharmabiotic Research Institute
Microbiome Project Manager

Day Two

Thursday, 27th January 2022

8:25 am | Equip and De-Risk Your Microbiome Drug Development for the European Market - Regulatory Science and a ‘Development-by- Design’ Approach

Charles Bundinof
Strain Discovery and Microbiome Science Lead
IFF

Track A - Afternoon - Day One

2:45 pm | Probiotic Consortia Improve Anti-viral Immunity to SARS-CoV-2 in Ferrets

Christophe Clarite
CMO
4D Pharma PLC

Day 2 - Track A Evening

4:05 pm | Delve Into Manufacturing and Controls of LBPs: Meeting GMP and Regulator guidelines

Denise Kelly
Investment Advisor
Seventure

Day 2 - Track A Evening

4:45 pm | Building Investor Confidence in Microbiome Drug Development; how to Promote And Restore Confidence

Day One

Wednesday, 26th January 2022

8:25 am | European Microbiome Leaders Panel Discussion

Dr John Weinberg
CSO
MaatT Pharma

Day 2 - Track B Afternoon

3:15 pm | Analyzing the Progress of the Oncology Landscape to Enable & Amplify Future Development in This Field

Dr. Adam Rosenthal
Health & Biosciences, Research & Development
IFF

PRE-CONFERENCE WORKSHOP DAY | TUESDAY 25TH JANUARY 2022 Workshop C - 'Identifying Drug Targets With Bacterial Single Cell Tools'

Dr. Nga Le
Process Engineer
Fluid Air

Day 2 - Track A Evening

4:35 pm | Low-Temperature Drying & Microencapsulation of Microbiomes

Duncan Peyton
CEO
4D Pharma PLC

Day One

Wednesday, 26th January 2022

8:25 am | European Microbiome Leaders Panel Discussion

Edward Green
CEO
CHAIN Biotechnology LTD

Track B - Afternoon - Day One

3:15 pm | Oral Drug Delivery to the Lower GI

Fabio Grassi
Founder
MV BioTherapeutics

Track A - Afternoon - Day One

1:45 pm | Microbiota Adaptation via Secretory IgA to Correct Dysbiosis

Felix Faupel
Chief Commercial Officer
Bacthera

Day One

Wednesday, 26th January 2022

12:15 pm | Solving LBP Manufacturing Challenges: Introducing BacThera & Industry Changing Downstream Technologies

Gabriel Leventhal
Head of R&D
PharmaBiome

Track A - Afternoon - Day One

3:15 pm | Next Steps for Omics: Niche Mapping the Microbiome to Gain a Functional Understanding of Dysbiosis

Georges Rawadi
CEO
YSOPIA Bio

Track A - Evening - Day One

4:15 pm | Christenssenella Minuta a Novel Live Biotherapy for Obesity and Metabolic Diseases

Grégoire Chevalier
Scientific Affairs Manager
Enterome

Track A - Evening - Day One

4:45 pm | Harnessing the Microbiome for Drug Discovery: the Example of a Microbiome-Derived Therapeutic for Ulcerative Colitis

Hervé Affagard
CEO
MaaT Pharma

Day One

Wednesday, 26th January 2022

8:25 am | European Microbiome Leaders Panel Discussion

Igor Stzepourginski
Head of Preclinical Operations
Eligo Bioscience

Day 2 - Track A Afternoon

3:15 pm | A Novel Therapeutic Approach for the Elimination of Harmful Bacteria From the Microbiome

Jack Gallagher
CEO
Clarity Pharma

Track B - Evening - Day One

5:15 pm | Optimizing the Exploding Power of Microbiome Predictive Analytics Will Require Applying the Laws of Behaviour and Risk Perception to Influence a Patient’s Downstream Health Decisions

Jeff Heiser
Head of Quality Control/Analytical Development
Arranta Bio

Day One

Wednesday, 26th January 2022

9:55 am | Investing in the Analytical Methods and Facilities for the Future of Live Biotherapeutic Products

Jenny Bailey
CEO
Ferryx

Day 2 - Track B Evening

4:45 pm | Inflammation, Iron And the gut Microbiome; Challenges for Mitigating the Effects of Inflammatory Bowel Disease Using LBPs

John Hambor
Director, Research Beyond Borders
Boehringer Ingleheim

Day One

Wednesday, 26th January 2022

9:25 am | Bacteria as Evolved Chemists: Microbial Bioactive Molecules are the Lexicon of Microbe-microbe and Microbe-host Communication

Karine Roget
CSO
Nexbiome

Day 2 - Track B Evening

4:35 pm | BGY-1601, Vaginal tablet: a “Universal” First-Line Monotherapy of Acute Vaginitis Symptoms

Ken J. Blount
CSO
Rebiotix

Day One

Wednesday, 26th January 2022

8:25 am | European Microbiome Leaders Panel Discussion

Day Two

Thursday, 27th January 2022

11:45 am | Embrace the New: How Rethinking the Microbiome Can Advance Therapeutics and Improve the Patient Experience

Kristin Wannerberger
Director R&D Alliance Management
Ferring

Day One

Wednesday, 26th January 2022

10:45 am | Ferring & the Microbiome

Luc Sterkman
CEO
Caelus Health

Day 2 - Track B Evening

4:05 pm | A Deep Dive Into the Potential of Microbiome Therapeutics in Cardiometabolic And Related Disorders

Lutz Kraus
Head of Data-Mining and Artifical Intelligence
Microba

Day Two

Thursday, 27th January 2022

9:25 am | Data Directed Discovery of Microbiome Derived Therapeutics

Manoj Dadlani
CEO
CosmosID

Day Two

Thursday, 27th January 2022

12:15 pm | Leveraging Strain-level Metagenomics in Developing Microbiome Therapeutics

Matthew Robinson
VP Translational Biology
Microbiotica

Day Two

Thursday, 27th January 2022

11:15 am | Using Precision Microbiome Profiling to Develop a Biomarker for Immune Checkpoint Inhibitor Response and a Potent Therapeutic Consortium

Mike Ramonas
CEO
Microbiotica

Day One

Wednesday, 26th January 2022

8:25 am | European Microbiome Leaders Panel Discussion

Nigel Horscroft
CSO
MRM Health

Day 2 - Track B Evening

5:35 pm | MRM Health’s Preclinical Optimized Consortia Programs in Metabolic Disease and CNS Disorders

Nigel Titford
CEO
BioGaia

Day One

Wednesday, 26th January 2022

11:15 am | From Probiotic Research to Drug Development Candidate

Nikhil Sharma
CEO
BiocorteX

Track B - Afternoon - Day One

1:45 pm | The Undiscovered Country: Microbiome Therapeutics

Paul Carlson
Principal Investigator
FDA

Day Two

Thursday, 27th January 2022

8:55 am | Regulatory Considerations for Microbiome Based Therapeutics

Rikke C Nielson
CEO and Founder
Beo Therapeutics

Track A - Afternoon - Day One

2:15 pm | Mode-Of-Action Directed Design of Microbial Therapies

Ryan Wilson
Head of Live Bio Programme
Quay Pharma

Day 2 - Track A Afternoon

1:45 pm | Development of Microbiome Drug Products

Sam Possemiers
CEO
MRM Health

Track A - Evening - Day One

5:15 pm | MH002, the first Optimized Consortia Therapeutic in Clinical Development for Ulcerative Colitis, Manufactured as Single Drug Substance

Sandrine Miller-Montgomery
President and CEO
Micronoma

Track B - Afternoon - Day One

2:45 pm | Rescuing Drugs From Failed Clinical Trials – Could the Microbiome Be of Use?

Shiri Meshner
VP R&D
Biomica LtD

Day One

Wednesday, 26th January 2022

11:45 am | From Functional Microbiome LBP Discovery to Clinical Proof of Concept

Sonia Timberlake
Senior Vice President
Finch

Track B - Evening - Day One

4:15 pm | A Human-First Discovery Approach: Leveraging Clinical Data to Identify Microbial Communities Driving Positive Clinical Outcomes

SPEAKER TBC

Luina Bio

Speaker TBC

Biose Industrie

Track B - Evening - Day One

4:05 pm | Talk Details To Be Confirmed

Todd Kruegar
President and CEO
AOBiome

Day 2 - Track B Afternoon

1:45 pm | Drug Development in the Skin Microbiome for the Treatment of Pruritus Associated with Atopic Dermatitis

Tom Van de Wiele
Chief Scientific Officer
ProDigest

Track A - Evening - Day One

4:05 pm | Delivery, Survival, Engraftment & Activity of LBPs in the GI Tract

Tomas de Wouters
Co-founder and CEO
PharmaBiome

Day 2 - Track A Afternoon

2:15 pm | Co-Cultivation is a Powerful Approach to Produce a Robust Functionally Designed Synthetic Consortium as a Live Biotherapeutic Product (LBP)

Yogesh Mudaliar
Global Millennial Advisory Board Member CEO
Takeda

Day 2 - Track A Afternoon

2:45 pm | Do’s and Don’ts’s of LBP lyophilization

Yvonne Nyavor
Principal Scientist
Boston Analytical

Day One

Wednesday, 26th January 2022

8:55 am | Microbiome Endgame: Preparing Microbiome Products for Regulatory Requirements Through cGMP Program Design